Bio-Techne (TECH) Set to Announce Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is set to release its earnings data before the market opens on Wednesday, May 1st. Analysts expect Bio-Techne to post earnings of $0.40 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Bio-Techne (NASDAQ:TECH) last announced its earnings results on Thursday, February 1st. The biotechnology company reported $0.33 earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.03). The firm had revenue of $272.60 million for the quarter, compared to the consensus estimate of $277.48 million. Bio-Techne had a return on equity of 14.21% and a net margin of 19.58%. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Up 0.7 %

TECH stock opened at $64.51 on Tuesday. The business’s fifty day moving average price is $69.68 and its two-hundred day moving average price is $68.44. The stock has a market capitalization of $10.14 billion, a price-to-earnings ratio of 46.75, a PEG ratio of 7.97 and a beta of 1.22. Bio-Techne has a fifty-two week low of $51.79 and a fifty-two week high of $89.91. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.37 and a quick ratio of 3.03.

Bio-Techne Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 26th. Investors of record on Monday, February 12th were given a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend was Friday, February 9th. Bio-Techne’s dividend payout ratio is 23.19%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TECH. Scotiabank initiated coverage on shares of Bio-Techne in a report on Thursday, February 8th. They set a “sector outperform” rating and a $80.00 target price on the stock. Stifel Nicolaus cut Bio-Techne from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a report on Friday, February 2nd. Deutsche Bank Aktiengesellschaft dropped their price target on Bio-Techne from $85.00 to $82.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. Royal Bank of Canada decreased their target price on shares of Bio-Techne from $85.00 to $75.00 and set a “sector perform” rating on the stock in a report on Friday, February 2nd. Finally, Stephens reduced their price target on shares of Bio-Techne from $92.00 to $87.00 and set an “overweight” rating on the stock in a research report on Friday, February 2nd. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $83.90.

Insider Activity

In related news, Director Roeland Nusse sold 10,400 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $76.98, for a total value of $800,592.00. Following the transaction, the director now owns 43,097 shares in the company, valued at $3,317,607.06. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 4.10% of the company’s stock.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.